Efficacy of encorafenib and cetuximab therapy in a young patient with a rare concomitant KRAS and BRAF mutation in primary rectal cancer and wild-type KRAS status in metastases: A case report and literature review
The presence of activating somatic mutations in the KRAS and NRAS oncogenes is a negative predictor of treatment with the anti-epidermal growth factor receptor (EGFR) monoclonal antibody in colorectal cancer. The BRAF oncogene also plays an important role in carcinogenesis, and, in colorectal cancer...
Main Authors: | Michal Eid, Martina Jelínková, Jiří Šána, Ondřej Slabý |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2022-12-01
|
Series: | Current Problems in Cancer: Case Reports |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2666621922000710 |
Similar Items
-
KRAS and BRAF Concomitant Mutations in a Patient with Metastatic Colon Adenocarcinoma: An Interesting Case Report
by: Concetta Cafiero, et al.
Published: (2020-06-01) -
The prevalence of KRAS and BRAF mutation in colorectal cancer patients in Bali
by: Ayu Dewi Ni Nyoman, et al.
Published: (2022-03-01) -
Correlation between KRAS, NRAS and BRAF mutations and tumor localizations in patients with primary and metastatic colorectal cancer
by: Aleksandra Bożyk, et al.
Published: (2021-03-01) -
High frequency of KRAS and EGFR mutation profiles in BRAF-negative thyroid carcinomas in Indonesia
by: Didik Setyo Heriyanto, et al.
Published: (2022-12-01) -
Molecular Pattern and Clinical Implications of KRAS/NRAS and BRAF Mutations in Colorectal Cancer
by: İvo Gökmen, et al.
Published: (2023-09-01)